Article
Collect the evidence; I'll look at it in a minute
We have good evidence and guidelines. Why aren't we using them more?
Reviews
Treating hyperglycemia in type 2 diabetes: New goals and strategies
Cleveland Clinic Journal of Medicine. 2002 October;69(10):809-820
Author and Disclosure Information
Harold E. Lebovitz, MD
Professor of Medicine, Division of Endocrinology and Metabolism/Diabetes, State University of New York (SUNY) Health Sciences Center, Brooklyn
Address: Harold E. Lebovitz, MD, 416 Henderson Avenue, Staten Island, NY 10310
Dr. Lebovitz has indicated that he has received grant or research support from the Bristol-Myers Squibb, GlaxoSmithKline, and Novo Nordisk corporations; serves as a consultant for the Amylin, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica, Merck-Lipha, Novartis, Novo Nordisk, Pfizer, and Takeda corporations; is on the speakers’ bureaus of all of the above plus the Aventis corporation; and is a major stock shareholder in the Bayer, Bristol-Myers Squibb, and GlaxoSmithKline corporations.
ABSTRACTTo achieve glycemic goals in type 2 diabetes, one must usually use combinations of oral agents or oral agents plus insulin. This paper discusses the metabolic derangements of type 2 diabetes, the different classes of antihyperglycemic drugs, and strategies for using these drugs rationally.